| 张天栋,武德珍,李奎,赵欣,左旭,孙彩艳,王培,布紫云.ABCB1(2677T>G)和SLCO1B1(521T>C)基因多态性对阿托伐他汀降脂疗效的影响[J].中国药事,2018,32(11):1558-1561 |
| ABCB1(2677T>G)和SLCO1B1(521T>C)基因多态性对阿托伐他汀降脂疗效的影响 |
| Effect of ABCB1 (2677T>G) and SLCO1B1 (521T>C) Gene Polymorphisms on Lipid-lowering Efficacy of Atorvastatin |
| 投稿时间：2018-01-16 |
| DOI：10.16153/j.1002-7777.2018.11.016 |
| 中文关键词: ABCB1(2677T>G) SLCO1B1(521T>C) 基因多态性 阿托伐他汀 降脂疗效 |
| 英文关键词: ABCB1 (2677T>G) SLCO1B1 (521T>C) gene polymorphisms atorvastatin lipid-lowering efficacy |
| 基金项目:新乡市科技攻关计划项目（编号CXGG16057） |
|
| 摘要点击次数: 1177 |
| 全文下载次数: 492 |
| 中文摘要: |
| 目的：探讨新乡地区人群ABCB1（2677T>G）、SLCO1B1（521T>C）基因多态性分布及其与阿托伐他汀降脂疗效的相关性。方法：采用荧光原位杂交方法，检测120例血脂异常患者ABCB1（2677T>G）、SLCO1B1（521T>C）基因型分布；入选患者每晚服用阿托伐他汀20 mg，连续用药4周后，检测用药前后血脂水平，评价降脂疗效。结果：在新乡市中心医院的120例入选患者中，ABCB1（2677T>G）和SLCO1B1（521T>C）基因突变频率分别为70.5%和21.8%，该基因分布符合Hardy-Weinberg平衡。携带ABCB1 2677GG型患者对LDL-C的调节作用显著高于同一位点的其他基因型，而其他血脂指标未见相关性。SLCO1B1（521T>C）各基因型患者间血脂变化差异无统计学意义。结论：携带ABCB1 2677GG基因型的患者接受阿托伐他汀治疗时，降脂疗效较佳。 |
| 英文摘要: |
| Objective: To investigate the association between the distribution of ABCB1 (2677T>G) and SLCO1B1 (521T>C) gene polymorphisms and lipid-lowering efficacy of atorvastatin (ATV) of the Xinxiang population. Methods: The distribution of genotypes of ABCB1 (2677T>G) and SLCO1B1 (521T>C) in 120 patients with dyslipidemia was determined by fluorescence in situ hybridization (FISH). The eligible patients were treated with 20 mg ATV once a day for 4 weeks. The levels of serum lipid before and after treatment were measured to evaluate the efficacy of lipid-lowering of ATV. Results: The frequencies of ABCB1 (2677T>G) and SLCO1B1 (521T>C) gene polymorphisms of the 120 patients in Xinxiang Central Hospital were 70.5% and 21.8%, respectively. The distribution of the gene polymorphisms was in Hardy-Weinberg equilibrium. Patients with ABCB1 2677GG showed significantly greater regulation of LDL-C in response to ATV therapy than those of other genotypes. No association was found in other serum lipid indicators. However, there was no significant difference in serum lipid among patients with genotypes of SLCO1B1 (521T>C). Conclusion: Patients with the ABCB1 2677GG genotype exhibited better lipid-lowering efficacy than other patients when treated with ATV. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |